Political gridlock could be good for biopharma
Split congressional control will result in more drug pricing talk, but don’t expect much action.
Pharma bends on US pricing debate
Disclosing prices to consumers looks like a fait accompli, although the details are still being debated. Icer, meanwhile, could open the door to biopharma’s early…
US opioid crisis package nears enactment
Medicare is to review ways to encourage use of non-addictive pain relievers, but Heron Therapeutics will miss out on extension of a special payment provision.
On patient-reported outcomes pharma wants to have its cake and eat it
Over industry objections, a Medicare panel endorses patient symptom reporting tools that could lower payments for drugs with a high side-effect burden.
How a discount programme became the villain in US drug price wars
Pharma sector pushes back against a programme that mandates cheaper prices for hospitals serving the poor.
Biosimilars the beneficiary of new Medicare step therapy rule
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
The million-dollar question hanging over US research funding law
As drug prices climb, is it time to ask whether the landmark technology transfer law is a fair deal for US taxpayers?
Despite the FDA’s best efforts, device approvals crash
Regulatory intervention having limited impact on fostering innovation.
Wrong to try?
Will US right-to-try legislation be a means of giving hope to terminally ill patients, or drug another way for drug regulatory standards to fall?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.